Literature DB >> 18645515

Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.

Vincent Marconi1, Sebastian Bonhoeffer, Roger Paredes, Jing Lu, Rebecca Hoh, Jeffery N Martin, Steven G Deeks, Daniel R Kuritzkes.   

Abstract

OBJECTIVES: To estimate the in vivo fitness cost of enfuvirtide (ENF) resistance, we analyzed dynamic shifts in the HIV-1 quasispecies under changing selective pressure in 3 subjects on failing ENF-based regimens who interrupted ENF while maintaining stable background regimens. Subsequently, ENF was readministered for 4 weeks as "pulse intensification."
METHODS: The proportion of plasma virus carrying the V38A mutation in gp41 was quantified by allele-specific real-time polymerase chain reaction in serial samples collected from 3 subjects at 1- to 4-week intervals. Fitness differences were calculated using a method that corrected for time dependence of the viral replication rate.
RESULTS: The V38A mutant made up >or=85% of the quasispecies at baseline and decayed to <5% over 12-24 weeks; plasma HIV-1 RNA levels remained stable during this time. Fitness differences for mutant versus wild type ranged from -25% to -65%, providing in vivo evidence for the reduced fitness of ENF-resistant HIV-1. The V38A mutant virus reemerged rapidly during the ENF pulse.
CONCLUSIONS: These results demonstrate that the HIV-1 quasispecies undergoes dynamic changes in response to withdrawal and reinitiation of fusion inhibitor therapy. The relative stability of plasma HIV-1 titers during decay of V38A suggests that factors other than viral fitness likely define viral load set-point in patients with advanced disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645515      PMCID: PMC2709806          DOI: 10.1097/QAI.0b013e31817bbc4e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype.

Authors:  Jacques Izopet; Corinne Souyris; Allan Hance; Karine Sandres-Sauné; Muriel Alvarez; Christophe Pasquier; François Clavel; Jacqueline Puel; Patrice Massip
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

2.  Procedures for reliable estimation of viral fitness from time-series data.

Authors:  Sebastian Bonhoeffer; Andrew D Barbour; Rob J De Boer
Journal:  Proc Biol Sci       Date:  2002-09-22       Impact factor: 5.349

3.  The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.

Authors:  Olivier Lambotte; Marie-Laure Chaix; Brigitte Gubler; Nadine Nasreddine; Christine Wallon; Cécile Goujard; Christine Rouzioux; Yassine Taoufik; Jean-François Delfraissy
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

4.  Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.

Authors:  Thomas E Melby; Michael Despirito; Ralph A Demasi; Gabrielle Heilek; James A Thommes; Michael L Greenberg; Neil Graham
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

5.  Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.

Authors:  C A Derdeyn; J M Kilby; G D Miralles; L F Li; G Sfakianos; M S Saag; R D Hockett; R P Bucy
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

6.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

8.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Authors:  Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

Review 9.  Glancing behind virus load variation in HIV-1 infection.

Authors:  Sebastian Bonhoeffer; Georg A Funk; Huldrych F Günthard; Marek Fischer; Viktor Müller
Journal:  Trends Microbiol       Date:  2003-11       Impact factor: 17.079

10.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

View more
  12 in total

1.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Authors:  Athe M N Tsibris; Zixin Hu; Roger Paredes; Kay E Leopold; Opass Putcharoen; Allison L Schure; Natalie Mazur; Eoin Coakley; Zhaohui Su; Roy M Gulick; Daniel R Kuritzkes
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

3.  Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

4.  Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load.

Authors:  Naveen K Vaidya; Libin Rong; Vincent C Marconi; Daniel R Kuritzkes; Steven G Deeks; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2010-11-24       Impact factor: 4.475

5.  A strong case for viral genetic factors in HIV virulence.

Authors:  Viktor Müller; Christophe Fraser; Joshua T Herbeck
Journal:  Viruses       Date:  2011-03-08       Impact factor: 5.818

Review 6.  Current perspectives on HIV-1 antiretroviral drug resistance.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Viruses       Date:  2014-10-24       Impact factor: 5.048

Review 7.  Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review.

Authors:  N Wagner; C A Wyler-Lazarevic; S Yerly; C Samer; G Peytavin; K M Posfay-Barbe; A Calmy; J Ambrosioni
Journal:  New Microbes New Infect       Date:  2015-02-27

8.  Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.

Authors:  Michele Smith; Jonathon Hoffman; Hakimuddin Sojar; Ravikumar Aalinkeel; Chiu-Bin Hsiao; Mark Daniel Hicar
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

Review 9.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

10.  Realistic three dimensional fitness landscapes generated by self organizing maps for the analysis of experimental HIV-1 evolution.

Authors:  Ramón Lorenzo-Redondo; Soledad Delgado; Federico Morán; Cecilio Lopez-Galindez
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.